State of the Sterile Fill-Finish Market 2024 Report

• The most up to date data and analysis of markets, pipelines, trends, outsourcing details, M&A and investments on the Sterile Fill-Finish Market, with exclusive insights from C-Level operating executives on context and implications. 

• The report will be invaluable to investors and dealmakers in CDMOs/Pharma Services, as well as executive leadership, senior management, sales and marketing teams at CDMOs to support informed decisions on future investments in Sterile Fill-Finish and to leverage attractive growth opportunities in this segment.

• Published by Expert Insights, the World's Leading Advisory Services, Investment Research and Strategy Consulting Firm in Pharma Services. Insights and analysis are based upon extensive primary and secondary research, interviews conducted with our real-world experienced operating executives, subject matter experts and industry key opinion leaders, and a thorough review of industry reports and market data.

• Sterile Fill-Finish Pipeline Constitutes ~X,XXX Assets, Growing at XX% CAGR Driven by Broad Growth Across Modalities 
• Top 3 Indications Constitute +XX% of the Injectable Pipeline 
• XXXX and XXXX Top Fill-Finish Technologies used for Marketed Injectables, while XXXX Appear Poised for Future Growth
• Overall Outsourced Market (Development & Commercial) for SF-F Services is Estimated at $XXB Growing at X.X% CAGR (4y)
• Outsourced Market Size For SF-F Development Injectable Programs is Estimated at $X.XB Growing at XX% CAGR (3y)
• Outsourcing Market Size By Sterile Fill-Finish Technologies: Growth Drivers Are XXXX and XXXX Estimated $X.XB at XX% CAGR (5y)
• Outsourcing SF-F Market By Region: XXXX Market is Nearly 2X Larger (+X7B) and 2X Faster Growing (XX%) than XXXX, Driven by XXXX and XXXX
• Key Trends and Market Developments Impacting Sterile Fill-Finish Segment
• GLP-1 Market is Enjoying Significant Growth and Predicted to be $XXX by 2030, Driving Massive Investment in In-House and Outsourced Large Scale PFS Capacity
• About XX% of all Commercial Injectable Products Are Outsourced Across All Technology Platforms: Overall Commercial Outsourcing rate is XX%
• Top Pharma Players Outsource XX% of all SF-F Manufacturing to Strategic Partners (CDMOs) to Mitigate Supply Chain And Production Risks
• Total Commercial Innovator Products (US, NA and Global, Aug 2024) by Top 20 Pharma Producers, by Different Sterile Fill-Finish Formats
• Top 10 Sterile Fill Finish CDMOs Support XX% of Marketed Commercial Products: CDMOs with End-to-End Services Have Greater Market Share
• Over XXX Injectable Sterile Fill-Finish Production Sites in North America (NA) and Europe: One-Third of All Sites, Dedicated Contracts or CDMOs
• Global Prefilled Syringe (PFS) Fill-Finish Site by Country and by Operating Model Type
• Top Competitors for Sterile Fill-Finish in Western Markets Include Multiple Players: Top CDMOs Contribute to XX% of All Approvals
• List of Major and Relevant Fill-Finish Outsourced Providers
• Massive Investments in Acquisitions, Site Expansions and New Capabilities by CDMOs to Address Growing Demand for Sterile Fill Finish Services and Expertise
• Expansions in Sterile Fill-Finish: Over $XXXM Invested New Sites Or Production Lines (2023-24) to Capitalize on Growth Shaped by Market Trends
• Acquisitions and Site Expansions in Sterile Fill-Finish
• Strategic M&As in Sterile Fill-Finish
• Top Sterile Fill-Finish Pharmaceutical Manufacturers and Their Growth Strategies
• And much more.

PHARMACEUTICAL & BIOTECH

AbbVie, Amgen, AstraZeneca, Baxter International, Bayer AG, BioNTech, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co, Endo Pharmaceutical, F. Hoffmann-La Roche, Gilead Sciences, GSK, Johnson and Johnson, Merck & Co, Moderna, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical, Teva Pharmaceutical

CDMOs:

Aenova, AGC Biologics, Ajinomoto, Alcami, Almac, Argonaut Manufacturing Services, August Bioservices, Bora Pharma Co, Bushu Pharma, Carbogen Amcis, Catalent Pharma Solutions, Curia, Delpharm, Fareva, Fujifilm Diosynth, Grand River Aseptic Manufacturing, INCOG, Jubilant HollisterStier, Lifecore Biomedical, Lonza, National Resilience, Northway Biotech, PCI Pharma, Pii, Recipharm, Samsung Biologics, Selkirk Pharma, Sharp Packaging, Siegfried Holdings, Simtra BioPharma Solutions, Singota Solutions, ten23 Health, ThermoFisher Patheon, Vetter, Wuxi STA, And many others.

DRUG MODALITIES

Antibody-Drug Conjugates (ADCs), Biologics, Cell and Gene Therapy, Glucagon-Like Peptide-1 (GLP-1s) and mRNA Vaccines

THERAPEUTIC AREAS & INDICATIONS

Cardiovascular, Central Nervous System, ENT Disorders, Gastrointestinal, Hormonal Disorders, Immunology, Infectious Diseases, Metabolic Disorders, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory, Women's Health